Benzinga | Mar 2, 2021 07:35AM EST

Neurocrine Biosciences Announces Phase II INTERACT Study Evaluating Luvadaxistat In Cognitive Impairment Associated With Schizophrenia Did Not Meet Primary Endpoint

SAN DIEGO, March 2, 2021 /PRNewswire/ -- Neurocrine Biosciences (NASDAQ:NBIX) today announced that investigational drug luvadaxistat (NBI-1065844/TAK-831) did not meet its primary endpoint in the Phase II INTERACT study in adults with negative symptoms of schizophrenia, as measured by the change from baseline on the PANSS NSFS at Day 84. Luvadaxistat met secondary endpoints of cognitive assessment, which merit further clinical evaluation. The adverse event profiles for luvadaxistat were consistent with previous trials. Takeda Pharmaceutical Company Limited ("Takeda") granted an exclusive license to Neurocrine Biosciences for seven pipeline programs, including luvadaxistat, in June 2020. The results from the Phase II INTERACT study are being evaluated to determine next steps for development activities.